L-Carnitine and Improved Clinical Symptoms

Doses used in studies

Time to effect

Median: 5 days · IQR 5 days–5 days · Range 5 days–5 days — Reported in 1 of 1 study

Safety in these studies

mortalityNo significant differencesix patients (14%) in the control group died due to the complications of COVID-19, while all patients in the intervention group survived
No significant differences were observed in terms of clinical symptoms; however, six patients (14%) in the control group died due to the complications of COVID-19, while all patients in the intervention group survived.
from: Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease:
Overall tolerabilityReported
No significant differences were observed in terms of clinical symptoms
from: Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease:

1 of 1 paper

Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study.